Shenqi Fuzheng injection adjuvant chemotherapy for advanced non-small cell lung cancer:a systematic review

SHENG Lei,FANG Ying-li,XU Miao,LI Yan

2013-01-01

Abstract:AIM To systematically evaluate effectiveness and safety of Shenqi Fuzheng Injection(SFI) adjuvant chemotherapy in the treatment of advanced non - small cell lung cancer(NSCLC) based on available data of clinical research.METHODS The Cochrane Library,Pubmed,EMbase,CBM,CNKI and VIP from 1989 to 2011 were searched electronically and randomized controlled trials(RCTs) about SFI plus chemotherapy for advanced NSCLC were included.The quality of included studies was assessed by two independent researchers according to the criteria recommended by the Cochrane Handbook for Systematic Reviews of Interventions and meta - analyses were performed for homogeneous studies using Cochrane Collaboration' s RevMan 5.1.RESULTS Thirty - eight RCTs involving 2 598 patients were included in meta-analyses.The quality of all studies was graded C.Meta - analyses showed that SFI plus regular treatment can significantly stabilize or improve quality of life[RR = 1.40,95%CI(1.30,1.52)],ameliorate the symptom of anorexia and hypodynamia[RR = 0.45,95%CI(0.30,0.68)].The incidence rate of severe(3 to 4 grade) leukocytopenia [RR = 0.41,95%CI(0.30,0.56)],thrombocytopenia[RR = 0.44,95%CI(0.32,0.60)],anemia[RR = 0.43,95%CI(0.28,0.66)],reactions of gastrointestinal tract[RR = 0.30,95%CI(0.21,0.42)]were lower in combined SFI and chemotherapy than in chemotherapy alone.The response rate of SFI adjuvant vinorelbine + cisplatin(NP) was superior to NP with RR = 1.19,95%CI(1.01,1.40).The response rate of SFI adjuvant paclitaxel + cisplatin(TP) was better than TP with RR = 1.30,95%CI(1.10,1.53).The response rate of SFI adjuvant gemcitabine + cisplatin(GP) was better than GP with RR = 1.24,95%CI(1.01,1.52).The response rate of SFI adjuvant docetaxel + cisplatin(DP) was similar to DP with RR = 1.04,95%CI(0.65, 1.68).Sensitive analyses revealed that the response rate of SFI adjuvant TP on advanced NSCLC was stable,but that of SFI adjuvant GP or NP was not.CONCLUSION The available evidence indicated that SFI could significantly improve or stabilize quality of life in patients with advanced NSCLC,ameliorate the symptom of anorexia and hypodynamia,reduce grade 3 or 4 chemotherapy - induced myelosuppression and reactions of gastrointestinal tract,improve the effect of TP on advanced NSCLC.However,the adjuvant effect of SFI to other regimens(GP,NP or DP) on advanced NSCLC need to be confirmed by further high-quality randomized clinical trials.